Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 6 completed trials have results

Key Signals

Enrollment Performance

Analytics

No phase data available

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT01354834Completed

Assessment of the Effectiveness of Menopur in Intrauterine Insemination

Role: collaborator

NCT01351818Completed

Adipocyte Function and Somtropin Deficiency

Role: collaborator

NCT01331720Completed

Assessment of the Effectiveness and Tolerability of Ovarian Hyperstimulation

Role: collaborator

NCT01331733Completed

Comparative Assessment of the Clinical Utility of Ovarian Stimulation With Menotropin Versus Menotropin Plus GnRH Antagonist

Role: collaborator

NCT01330771Completed

Assessment of the Therapeutic Utility of r-FSH in Association With hMG-HP

Role: collaborator

NCT01330784Completed

Assessment of the Therapeutic Utility of hMG-HP

Role: collaborator

All 6 trials loaded